Johnson & Johnson at JPMorgan Healthcare Conference Summary - Thomson StreetEvents

Johnson & Johnson at JPMorgan Healthcare Conference Summary

Johnson & Johnson at JPMorgan Healthcare Conference Summary - Thomson StreetEvents
Johnson & Johnson at JPMorgan Healthcare Conference Summary
Published Jan 13, 2025
12 pages (7117 words) — Published Jan 13, 2025
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Brief of JNJ.N presentation 13-Jan-25 5:00pm GMT

  
Brief Excerpt:

...A. One is that we have the financial strength to be able to do deals like Intra-Cellular that we announced today, which, by the way, it's going to lift our sales growth versus what is considered today in the analyst models immediately and through the rest of the decade. B. That's a medical device drug combination that we have guided that is going to be more than a $5 billion product....

  
Report Type:

Brief

Source:
Thomson StreetEvents
Company:
Johnson
Ticker
JNJ.N
Time
5:00pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Chris Schott - JP Morgan - Analyst : Right. About a year ago you put out a annual top line growth target of 5% to 7% 2025 through 2030 for the total company. What is your comfort today with hitting that target? And what do you see as the key drivers of getting to that type of growth rate?

Question: Chris Schott - JP Morgan - Analyst : Great. Maybe turning to the big news of the day, the acquisition of ITCI. [Would you just help] highlight a little bit more on what brought you to that asset and how you see Caplyta fitting into the broader J&J portfolio?

Question: Chris Schott - JP Morgan - Analyst : Right. All sounds great for the long term. One of the nearer term questions we get I think is around the 3% growth target for J&J for 2025. Can you just go through some of the pushes and pulls that give you confidence in that target for -- as we think about this?

Question: Chris Schott - JP Morgan - Analyst : But the underlying kind of operational piece, you're feeling very --?

Question: Chris Schott - JP Morgan - Analyst : Maybe just pivoting a little bit to some of the administration dynamics. Just first of all, you went through the initial IRA price negotiation discussions last year as a company. Maybe just what are some of your main takeaways from that process and kind of where J&J ended up with those discussions? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JANUARY 13, 2025 / 5:00PM, JNJ.N - Johnson & Johnson at JPMorgan Healthcare Conference

Question: Chris Schott - JP Morgan - Analyst : What was the one you had the -- you had XARELTO in there too.

Question: Chris Schott - JP Morgan - Analyst : And just with the new administration coming in this year, just how are you thinking about the potential for change within the healthcare regulatory environment? I guess, what's top of mind for you?

Question: Chris Schott - JP Morgan - Analyst : Maybe pivoting to the pharma business. No more detail. Just immunology first. STELARA is facing biosimilars this year, it's one of your largest products. Latest on erosion curve and how we should think about analogies to think about as STELARA starts to see competition.

Question: Chris Schott - JP Morgan - Analyst : Just one thought there. Just as I think about the IL-23 market, TREMFYA versus the oral IL-23, how do you see those two playing off against each other?

Question: Chris Schott - JP Morgan - Analyst : Right. Maybe looking at one of your big franchises, myeloma seems like one of these end-to-end opportunities that you were talking about earlier. Just talk about the prospects for growth when you think about the portfolio of assets the companies put together.

Question: Chris Schott - JP Morgan - Analyst : Right. Maybe one last one on the pharma side. You also have a broad portfolio of assets and pipeline. Where do you see the most significant disconnects between J&J's internal view and how The Street is thinking about the pharma business?

Question: Chris Schott - JP Morgan - Analyst : Maybe pivoting over to MedTech. I know improving the growth prospects and kind of positioning this franchise was one of your key priorities during your tenure as CEO. A few years into this process, we'd just like to get your sense of where we are in that process? Kind of like what inning in the -- of repositioning do you feel J&J is at this point?

Question: Chris Schott - JP Morgan - Analyst : Maybe just one quick comment on VARIPULSE some of the recent news. What should we be watching there? And what are the next steps to think about?

Question: Chris Schott - JP Morgan - Analyst : Great. Maybe in the last couple of minutes here. Obviously, we're coming off a big announcement of a deal today, but just the latest priorities for J&J as we think both MedTech and pharma from here. What should we be thinking about in terms of priorities for you as you think about kind of further expanding the portfolio via BD?

Question: Chris Schott - JP Morgan - Analyst : Excellent. Well, I think we're just out of time. Joaquin, thanks so much for joining us. Really appreciate the comments today.

Table Of Contents

Johnson & Johnson at TD Cowen Healthcare Conference Summary – 2025-03-04 – US$ 54.00 – Edited Brief of JNJ.N presentation 4-Mar-25 4:10pm GMT

Johnson & Johnson at TD Cowen Healthcare Conference Transcript – 2025-03-04 – US$ 54.00 – Edited Transcript of JNJ.N presentation 4-Mar-25 4:10pm GMT

Johnson & Johnson Q4 2024 Earnings Call Summary – 2025-01-22 – US$ 54.00 – Edited Brief of JNJ.N earnings conference call or presentation 22-Jan-25 1:30pm GMT

Johnson & Johnson Q4 2024 Earnings Call Transcript – 2025-01-22 – US$ 54.00 – Edited Transcript of JNJ.N earnings conference call or presentation 22-Jan-25 1:30pm GMT

Johnson & Johnson at JPMorgan Healthcare Conference Transcript – 2025-01-13 – US$ 54.00 – Edited Transcript of JNJ.N presentation 13-Jan-25 5:00pm GMT

Johnson & Johnson at Stifel Healthcare Conference Summary – 2024-11-18 – US$ 54.00 – Edited Brief of JNJ.N presentation 18-Nov-24 3:55pm GMT

Johnson & Johnson at Stifel Healthcare Conference Transcript – 2024-11-18 – US$ 54.00 – Edited Transcript of JNJ.N presentation 18-Nov-24 3:55pm GMT

Johnson & Johnson at Guggenheim Global Healthcare Conference Summary – 2024-11-12 – US$ 54.00 – Edited Brief of JNJ.N presentation 12-Nov-24 3:30pm GMT

Johnson & Johnson at Guggenheim Global Healthcare Conference Transcript – 2024-11-12 – US$ 54.00 – Edited Transcript of JNJ.N presentation 12-Nov-24 3:30pm GMT

Johnson & Johnson Q3 2024 Earnings Call Summary – 2024-10-15 – US$ 54.00 – Edited Brief of JNJ.N earnings conference call or presentation 15-Oct-24 12:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Johnson & Johnson at JPMorgan Healthcare Conference Summary" Jan 13, 2025. Alacra Store. May 02, 2025. <http://www.alacrastore.com/thomson-streetevents-transcripts/Johnson-Johnson-at-JPMorgan-Healthcare-Conference-B16209226>
  
APA:
Thomson StreetEvents. (2025). Johnson & Johnson at JPMorgan Healthcare Conference Summary Jan 13, 2025. New York, NY: Alacra Store. Retrieved May 02, 2025 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Johnson-Johnson-at-JPMorgan-Healthcare-Conference-B16209226>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.